Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Moll

Showing results (81-90 of 129) with videos related to

Pageof 13
Sort By:
Blood Advances|September 18, 2023
Evaluating complement dysregulation in livedoid vasculopathy using a functional assayHarish Eswaran, Shruti Chaturvedi, Robert A Brodsky, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 29, 2021
Emicizumab reduces re-hospitalization for bleeding in acquired haemophilia ASheh-Li Chen, Patrick Ellsworth, Raj S Kasthuri, et al.
Research and Practice in Thrombosis and Haemostasis|March 18, 2021
Vascular thromboembolic events following COVID-19 hospital discharge: Incidence and risk factorsHarish Eswaran, Jamie A Jarmul, Amy W Shaheen, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 28, 2004
Percutaneous coronary intervention in a patient with immune thrombocytopenia purpuraGeorge A Stouffer, Jana Hirmerova, Stephan Moll, et al.
American Journal of Hematology|December 25, 2019
Adherence to infectious disease screening and immunization guidelines when treating non-malignant immune-mediated hematologic disordersLuis E Malpica-Castillo, Shannon Palmer, Anqi Zhu, et al.
American Journal of Hematology|February 5, 2020
Incidence and time course of neutropenia in patients treated with rituximab-based therapy for non-malignant immune-mediated hematologic diseasesLuis E Malpica Castillo, Shannon Palmer, Anqi Zhu, et al.
Leukemia & Lymphoma|April 11, 2017
Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: a retrospective cohortDamon E Houghton, Nigel S Key, Neil A Zakai, et al.
The American Journal of Medicine|September 4, 2012
Incidence of thrombocytopenia among patients receiving heparin venous thromboembolism prophylaxisTracy Y Wang, Emily F Honeycutt, Victor F Tapson, et al.
Thrombosis and Haemostasis|October 4, 2002
Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpuraMargaret E Rick, Stephan Moll, Mark A Taylor, et al.
The Annals of Pharmacotherapy|April 10, 2015
Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level?Robert C Gosselin, Suzanne J Francart, Emily M Hawes, et al.
Pageof 13

Showing results (81-90 of 129) with videos related to

Sort By:
Pageof 13
Blood Advances|September 18, 2023
Evaluating complement dysregulation in livedoid vasculopathy using a functional assayHarish Eswaran, Shruti Chaturvedi, Robert A Brodsky, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 29, 2021
Emicizumab reduces re-hospitalization for bleeding in acquired haemophilia ASheh-Li Chen, Patrick Ellsworth, Raj S Kasthuri, et al.
Research and Practice in Thrombosis and Haemostasis|March 18, 2021
Vascular thromboembolic events following COVID-19 hospital discharge: Incidence and risk factorsHarish Eswaran, Jamie A Jarmul, Amy W Shaheen, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 28, 2004
Percutaneous coronary intervention in a patient with immune thrombocytopenia purpuraGeorge A Stouffer, Jana Hirmerova, Stephan Moll, et al.
American Journal of Hematology|December 25, 2019
Adherence to infectious disease screening and immunization guidelines when treating non-malignant immune-mediated hematologic disordersLuis E Malpica-Castillo, Shannon Palmer, Anqi Zhu, et al.
American Journal of Hematology|February 5, 2020
Incidence and time course of neutropenia in patients treated with rituximab-based therapy for non-malignant immune-mediated hematologic diseasesLuis E Malpica Castillo, Shannon Palmer, Anqi Zhu, et al.
Leukemia & Lymphoma|April 11, 2017
Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: a retrospective cohortDamon E Houghton, Nigel S Key, Neil A Zakai, et al.
The American Journal of Medicine|September 4, 2012
Incidence of thrombocytopenia among patients receiving heparin venous thromboembolism prophylaxisTracy Y Wang, Emily F Honeycutt, Victor F Tapson, et al.
Thrombosis and Haemostasis|October 4, 2002
Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpuraMargaret E Rick, Stephan Moll, Mark A Taylor, et al.
The Annals of Pharmacotherapy|April 10, 2015
Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level?Robert C Gosselin, Suzanne J Francart, Emily M Hawes, et al.
Pageof 13